Anders Karlsson has been appointed new CEO for the company and he will take up his new position on August 19, 2019.
Anders Karlsson has a broad experience from a range of pharma and medtech companies, including leading positions at Novartis and Olerup International.
”Idogen has ground-breaking development projects within immunology and transplantation, areas which I have worked actively with over the years and where I see tremendous potential. Idogen’s product pipeline can develop into lifesaving treatments for many severely ill patients in the future. With its skilled employees, the company is well positioned for value creation in the coming years and I look forward to lead the company through that journey,” says Anders Karlsson, incoming CEO of Idogen.
Most recently, Anders Karlsson served as CEO of Allenex AB where he managed the merger with CareDx Inc. In his previous positions, he has successfully re-positioned companies and negotiated global cooperation agreements, states Idogen.
”We are very pleased with the recruitment of Anders Karlsson. His combined experience from both the pharma and medtech industries, and renowned management skills, will be of great value for Idogen. Anders has a strong business acumen and has contributed to significant value creation on multiple occasions in his previous roles. The Board of Directors look forward to continue the development of Idogen together with Anders,” comments Idogen’s chairman Agneta Edberg.
Lars Hedbys leaves his position after 5 years as CEO
At the end of June, Lars Hedbys announced that he resigns after five years as CEO of Idogen. Hedbys is one of the co-founders of the company and he has held several positions at the company since the foundation.
”Efter 5 år som vd och med en ny toleransinducerare som kan bära vår cellterapi, är det en bra tid att lämna över stafettpinnen till nästa person. Idogen är ett fantastiskt företag med ett mycket starkt team och jag är övertygad om att det skall bli en framgångsrik fortsättning ” säger Lars Hedbys, vd i Idogen.